A Study of Cebranopadol for the Treatment of Acute Pain After Bunionectomy
Public ClinicalTrials.gov record NCT06423703. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled Study to Evaluate the Efficacy and Safety of Cebranopadol for the Treatment of Moderate to Severe Acute Pain After Primary Unilateral Bunionectomy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the efficacy and safety of Cebranopadol for acute pain after a bunionectomy.
Study identification
- NCT ID
- NCT06423703
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 240 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 18, 2024 (Actual)
- Primary completion
- Jan 31, 2025 (Actual)
- Completion
- Jan 31, 2025 (Actual)
- Last update posted
- Jan 26, 2026
2024 – 2025
United States locations
- U.S. sites
- 10
- U.S. states
- 8
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| ALLEVIATE 2 Site 001108 | Sheffield | Alabama | 35660 | — |
| ALLEVIATE 2 Site 001106 | Little Rock | Arkansas | 72211 | — |
| ALLEVIATE 2 Site 001103 | Tampa | Florida | 33613 | — |
| ALLEVIATE 2 Site 001102 | Atlanta | Georgia | 30331 | — |
| ALLEVIATE 2 Site 001107 | Overland Park | Kansas | 66212 | — |
| ALLEVIATE 2 Site 001105 | Pasadena | Maryland | 21122 | — |
| Alleviate 2 001113 | Houston | Texas | 77043 | — |
| ALLEVIATE 2 Site 001104 | McAllen | Texas | 78501 | — |
| ALLEVIATE 2 Site 001111 | San Antonio | Texas | 78240 | — |
| ALLEVIATE 2 Site 001101 | Salt Lake City | Utah | 84107 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06423703, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 26, 2026 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06423703 live on ClinicalTrials.gov.